1. Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer
- Author
-
Yongzhong Yao, Miao-Qun Xue, Jian-Feng Sang, Lei Su, and Jun Liu
- Subjects
breast cancer stem cells ,0301 basic medicine ,CA15-3 ,Oncology ,medicine.medical_specialty ,Biopsy ,neo-adjuvant chemotherapy ,Gene Expression ,CA 15-3 ,Breast Neoplasms ,Receptors, Interleukin-8A ,03 medical and health sciences ,breast cancer ,0302 clinical medicine ,Breast cancer ,Breast Fibroadenoma ,Internal medicine ,medicine ,Humans ,Breast ,skin and connective tissue diseases ,Survival rate ,Aged ,Neoplasm Staging ,CXCR1 ,business.industry ,chemokine receptor ,Cancer ,Middle Aged ,Prognosis ,medicine.disease ,Combined Modality Therapy ,Immunohistochemistry ,Neoadjuvant Therapy ,Tumor Burden ,Treatment Outcome ,030104 developmental biology ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Female ,Breast disease ,Neoplasm Grading ,Breast carcinoma ,business ,Follow-Up Studies ,Research Paper - Abstract
// Miao-Qun Xue 1 , Jun Liu 2 , Jian-Feng Sang 1 , Lei Su 1 and Yong-Zhong Yao 1 1 Department of General Surgery, Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China 2 Department of General Surgery, The Jiang Bei People’s Hospital of Nanjing, Nanjing 210048, China Correspondence to: Yong-Zhong Yao, email: cnyongzhongyao321@yeah.net Keywords: breast cancer, breast cancer stem cells, chemokine receptor, CXCR1, neo-adjuvant chemotherapy Received: October 12, 2016 Accepted: February 22, 2017 Published: April 06, 2017 ABSTRACT Objective: To investigate chemokine receptor CXCR1 expression characteristic in different breast tissues and analyze the relationship between CXCR1 expression changes in breast cancer tissue and efficacy of neo-adjuvant chemotherapy. Results: Chemokine receptor CXCR1 was lowly expressed in normal breast tissues and breast fibroadenoma, but highly expressed in breast cancer. It was significantly correlated with pathological stage, tumor cell differentiation, and lymph node metastasis ( P < 0.05). After neo-adjuvant chemotherapy, CXCR1 expression in breast cancer tissues decreased. Among these 104 breast cancer patients with different molecular subtypes, the survival rate with Luminal A was the highest, followed by the Luminal B breast cancer, TNBC was the worst. Materials and Methods: 104 cases with breast carcinoma, 20 cases with normal breast and 20 cases with breast fibroadenoma were included and followed up. Immunohistochemistry was used to detect the expression of CXCR1 in the various tissues. The relationship between the CXCR1 expression changes in breast cancer biopsies and surgical specimens, as well as the efficacy of neo-adjuvant chemotherapy, was analyzed. Conclusions: Chemokine receptor CXCR1 could be used as an indicator to predict benign or malignant breast disease, and it can even predict the malignancy degree of breast cancer, as well as its invasive ability and prognosis.
- Published
- 2017